This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

FTC opposes Boehringer's attempt to delay production of documents

( June 22, 2015, 17:45 GMT | Official Statement) -- MLex Summary: The US Federal Trade Commission has filed an opposition to Boehringer Ingelheim Pharmaceuticals’ motion to stay a mandate by the US Court of Appeals for the District of Columbia pending its petition for certiorari. Under the mandate, Boehringer would have to provide the FTC certain fact-based work products regarding the company’s settlement and copromotion agreement with Barr Pharmaceuticals. The FTC argues that the Supreme Court is very unlikely to review this case and that Boehringer has failed to show it would suffer irreparable harm absent a stay. See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections